News
28 April 2010 - Ergomed announces continued growth of its Dubai operations Print

Dubai, UAE - 28 April 2010
ERGOMED, the international clinical development services company is continuing to grow its Middle East operations from its regional headquarters in Dubai.
 
8 Feb 2010 - ERGOMED announces the opening of its Cambridge office Print

Cambridge, UK - 8 February 2010
ERGOMED announced today that it has expanded its UK operations with the opening of a Cambridge office and the recruitment of Neil Clark (ex-CeNeS Pharmaceuticals) as Chief Finance Officer and Dr Marco Bocci (ex-Alizyme) as Business Development Manager.
 
6 May 2009 - ERGOMED signs Co-Development collaboration agreement with Genzyme Corporation to develop Tasidotin in oncology Print

Frankfurt, Germany - 6 May 2009
ERGOMED announced today that it has signed an agreement with Genzyme Corporation on the co-development of tasidotin, a novel dolastatin analogue that has shown efficacy signals and a good safety profile in previous oncology clinical trials.
 
3 Feb 2009 - PrimeVigilance – a new company has been formed and has already commenced trading Print

UK - 3 February 2009
Founded by two globally respected experts, the newly formed PrimeVigilance Ltd. provides a unique offering in the field of pharmacovigilance (PV).
 
15 Jan 2009 - ERGOMED appointed preferred provider to Light Sciences Oncology (LSO) Print

Frankfurt (Germany) / Seattle (USA) - 15 January 2009
ERGOMED Group, the specialized international clinical development company, today announced that it has become a preferred provider to Light Sciences Oncology (LSO), the developer of Light Infusion Therapy™ (Litx™), an innovative light-activated drug treatment for solid tumours and other conditions.